Comparison · NCT02544152-6622d58a
Lubiprostone vs Placebo: Number of Participants Classified as an Overall Responder for IBS Symptoms
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lubiprostone vs Placebo: Number of Participants Classified as an Overall Responder for IBS Symptoms. Trial comparisons, record NCT02544152-6622d58a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02544152-6622d58a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.27 | 0.154 | 0.43 | wilson | |
| Risk in group 2 | 0.324 | 0.191 | 0.492 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0533 | -0.258 | 0.154 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.835 | 0.407 | 1.71 | log | |
| Odds ratio, group 1 over group 2 | 0.774 | 0.279 | 2.15 | log | |
| Number needed to treat, for one fewer participant with the outcome on Lubiprostone than on Placebo | 18.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lubiprostone | Participants receive 8 mcg lubiprostone capsules BID | 10 | 37 | OG001 |
| Group 2 | Placebo | Participants receive 0 mcg capsules twice daily (BID) | 11 | 34 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Classified as an Overall Responder for IBS Symptoms
- Description
- A participant who is a weekly responder for IBS symptoms for at least 75% of observed treatment weeks is classified as an overall responder for IBS symptoms.
- Time frame
- within 3 months
- Population
- mITT
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome
- NCT number
- NCT02544152
- Phases
- PHASE2
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Lubiprostone, Placebo
- Lead sponsor
- Sucampo Pharma Americas, LLC
- Results first posted
- 2019-12-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02544152?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02544152-6622d58a